Kintara Therapeutics Inc KTRA

Healthcare Biotechnology

Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.

NDAQ:KTRA - Post by User

Kintara Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by biggdealon Sep 27, 2021 4:31pm

115 Views

Post# 33925547

Loading up at .88 this is $3.00 all day long

The shorts are playing a dirty game with this stock. Funding the company for 15m and immediately taking the issued stock to short their own investment. This will reverse and they will go long jamming the share price back up. It's a dirty game folks but lot's of profit to be made here! The fundamentals all line up on this company and this is SO OVERSOLD!!!!

<< Previous

Bullboard Posts

Next >>

Nickelex Resource to acquire Arlington Gold Property